Literature DB >> 26123311

Leiomyosarcoma: investigation of prognostic factors for risk-stratification model.

Hyun Ju Kim1,2, Yong Jin Cho3, Soo Hee Kim4, Sun Young Rha1, Joong Bae Ahn1, Woo Ick Yang4, Young Han Lee5, Jin-Suck Suh5, Jae Kyung Roh1, Kyung Sik Kim6, Young Deuk Choi7, Kyoo-Ho Shin8, Hyo Song Kim9.   

Abstract

BACKGROUND: We performed this study to define distinctive clinical features of leiomyosarcoma by assessing prognostic factors.
METHODS: Between 1988 and 2011, 129 leiomyosarcoma patients who underwent surgical resection with curative intent were retrospectively reviewed.
RESULTS: Of the 129 leiomyosarcoma patients, the distribution of anatomic locations was: extremity (n = 25), pelvis (n = 40), thoracic cavity (n = 11), intra-abdomen (n = 19), retroperitoneum (n = 23), and head/neck (n = 11). We classified the anatomic locations into two categories as abdominal (intra-abdomen and retroperitoneum, n = 42) and extra-abdominal (extremity, pelvis, thoracic cavity, and head/neck, n = 87). Prognosis was worse for the abdominal group than for the extra-abdominal group (median DFS 2.9 9.0 years, P = 0.04). Similarly, overall survival (OS) was also significantly worse for abdominal group (P = 0.027). Independent prognostic factors for survival were primary site (P = 0.041, hazard ratio (HR) 1.7; 95 % CI 1.2-2.8), tumor size (P = 0.038, HR 1.9; 95 % CI 1.13-3.38), margin status (P = 0.019, HR 2.1; 95 % CI 1.13-3.88), and histology grade (P = 0.01, HR 3.59; 95 % CI 1.64-7.87). We identified four different risk groups with different survival outcome: group 1 (n = 8), no adverse factors; groups 2 (n = 37) and 3 (n = 61) with one and two adverse factors, and group 4 (n = 23) with 3 or 4 adverse factors.
CONCLUSION: Primary site, tumor size, resection margin, and histology subtype were independently associated with survival outcome. A prognostic model for leiomyosarcoma patients revealed four distinct groups of patients with good prognostic discrimination.

Entities:  

Keywords:  Leiomyosarcoma; Prognostic factors; Risk stratification model

Mesh:

Year:  2015        PMID: 26123311     DOI: 10.1007/s10147-015-0847-y

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  17 in total

1.  Leiomyosarcoma of the prostate. Report of 23 cases.

Authors:  J C Cheville; P A Dundore; A G Nascimento; M Meneses; E Kleer; G M Farrow; D G Bostwick
Journal:  Cancer       Date:  1995-10-15       Impact factor: 6.860

2.  Cutaneous and subcutaneous leiomyosarcoma: a clinicopathological review of 14 cases with reference to antidesmin staining and nuclear DNA patterns studied by flow cytometry.

Authors:  G F Oliver; H M Reiman; N J Gonchoroff; S A Muller; I J Umbert
Journal:  Br J Dermatol       Date:  1991-03       Impact factor: 9.302

3.  Leiomyosarcoma of the skin and subcutaneous tissue of the hand and wrist.

Authors:  M M DeHart; M W Bowyer; R Silenas
Journal:  J Hand Surg Am       Date:  1992-05       Impact factor: 2.230

4.  Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy.

Authors:  Robert L Giuntoli; Daniel S Metzinger; Connie S DiMarco; Stephen S Cha; Jeff A Sloan; Gary L Keeney; Bobbie S Gostout
Journal:  Gynecol Oncol       Date:  2003-06       Impact factor: 5.482

5.  A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study.

Authors:  G A Omura; J A Blessing; F Major; S Lifshitz; C E Ehrlich; C Mangan; J Beecham; R Park; S Silverberg
Journal:  J Clin Oncol       Date:  1985-09       Impact factor: 44.544

6.  Leiomyosarcoma of the skin and subcutaneous tissue.

Authors:  B V Jegasothy; R S Gilgor; M Hull
Journal:  Arch Dermatol       Date:  1981-08

7.  Malignant smooth muscle tumors of the retroperitoneum and mesentery: a clinicopathologic analysis of 44 cases.

Authors:  H Hashimoto; M Tsuneyoshi; M Enjoji
Journal:  J Surg Oncol       Date:  1985-03       Impact factor: 3.454

8.  Leiomyosarcoma of the skin and subcutaneous tissue.

Authors:  J P Fields; E B Helwig
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

9.  Leiomyosarcoma of soft tissue: a clinicopathologic study.

Authors:  A G Wile; H L Evans; M M Romsdahl
Journal:  Cancer       Date:  1981-08-15       Impact factor: 6.860

10.  Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).

Authors:  Martee L Hensley; J Kyle Wathen; Robert G Maki; Dejka M Araujo; Gregory Sutton; Dennis A Priebat; Suzanne George; Robert A Soslow; Laurence H Baker
Journal:  Cancer       Date:  2013-01-18       Impact factor: 6.860

View more
  3 in total

1.  Important prognostic factors in leiomyosarcoma survival: a National Cancer Database (NCDB) analysis.

Authors:  J Gootee; N Sioda; S Aurit; C Curtin; P Silberstein
Journal:  Clin Transl Oncol       Date:  2019-08-07       Impact factor: 3.405

2.  A Case of "en bloc" Excision of a Chest Wall Leiomyosarcoma and Closure of the Defect with Non-Cross-Linked Collagen Matrix (Egis®).

Authors:  Marco Rastrelli; Saveria Tropea; Romina Spina; Alessandra Costa; Roberto Stramare; Simone Mocellin; Maria Giuseppina Bonavina; Carlo Riccardo Rossi
Journal:  Case Rep Oncol       Date:  2016-10-20

3.  Leiomyosarcoma of the chest wall mimicking schwannoma resected by a video-assisted thoracoscopic approach: a case report.

Authors:  Saki Yamamoto; Masahide Hirose; Takeshi Oyaizu; Aya Muramatsu; Makoto Suzuki; Shinichiro Ohta
Journal:  J Surg Case Rep       Date:  2022-01-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.